Translational Haematology

Our Translational Hematology group was created with the aim of generating knowledge in the field of hematology and collaborating with other groups for the implementation of projects. Our activity is based on a broad portfolio of clinical trials, basic research projects and registry studies. The area of knowledge in which we focus is the study of the immune system and its relationship with oncohematological diseases and their infectious complications, cell therapy, study of the adverse effects of drugs and optimization in obtaining and using blood components in Transfusion Therapy.

2025 Activity indicators

3 competitive public projects: ISCIII
1 competitive European project: H2020
2 private projects led
113 clinical studies
38 publications
IF: 262.20
Publications in Q1: 27 (71%)
Publications in D1: 14 (37%)
1 doctoral thesis supervised and defended
1 award
Project evaluators from national and international institutions: 4 researchers
Editorial committee members: 1 PI
11 visiting researchers hosted and 43 months of stay: Polytechnic University of Madrid

Milestones

Consolidation of research in advanced therapies: development of constructs, non-neoplastic diseases, and treatment of resistant viral infections.
Integration of bioengineering into care processes related to hematopoietic stem cell transplantation and advanced therapies.
Development of oncogeriatric assessment programs, improvement of patient performance status during therapy, and a patient education program.
Luna A, Devlin SM, Rejeski K, Flynn Jr., Corona M, Luttwak E, Rivas A, Landego I, Cassanello G, Gomez M, Raj SS, Dahi PB, Lin RJ, Parascondola A, Palomba ML, Shah GL, Scordo M, Alarcon A, Leithner D, Bedmutha A, Schöder H, Imber BS, Salles G, Park JH, Perales MA, Shouval R. CAR T-cell therapy response varies by extranodal disease site in large B-cell lymphoma. Blood Cancer J. 2025;15(1): 64 - 64. DOI:10.1038/s41408-025-01273-1.
Pérez L, Segura A, García R, Álvarez A, Senin MA, Mora E, Fox ML, Pastor I, Azaceta G, Garrido S, Pérez R, Trejos DM, Angona A, Albo C, Lorente P, Vara M, Vera JA, De Miguel D, Fernández Á, Marín A, Hernando A, Gómez MT, Stuckey R, Carreño G, De Las Heras N, Xicoy B, Pérez M, Mata R, Núñez Martin L, Ferrer F, Amer N, Guillén C, Velez P, Lamarca L, Martín S, Luts I, De Cabo E, Gil A, Martín S, Marco De Lucas F, Otero Martinez MJ, Martín ML, Arquero T, Cabezudo E, López LA, Martínez Á, Tejedor A, Herrera de Pablo E, Mata MI, Castillo I, Fernández MJ, Aguilar C, Santaliestra M, García A, Navas B, Duran MA, Pérez M, Hernández T, Muñoz MÁ, Dávila J, Torres W, Gonzálvez JA, Torres HA, Cobo T, Abuin A, Pérez F, Osorio S, Beneit P, Peralta R, Herrera F, Cañamero E, Jiménez R, Gasior M, González De Villambrosia S, Tercero MT, Menéndez M, Cuevas B, Fonseca M, Garcés S, de La Puerta R, Lorenzo Á, Hernández JC, García V. Real world outcomes of momelotinib in myelofi brosis patients with anemia: results from the MOMGEMFIN study. Blood Cancer J. 2025;15(1): 67 - 67. DOI:10.1038/s41408-025-01275-z.